Michael John Zobel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael John Zobel has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Eugene S. Kim
Childrens Hosp Los Angeles, Div Pediat Surg, Los Angeles, CA USA
3 shared publications - Benjamin E. Padilla
Division of Pediatric Surgery, Department of Surgery, University of California, San Francisco.
2 shared publications - Benjamin E. Padilla
Division of Pediatric Surgery, Phoenix Children's Hospital, Phoenix, AZ, USA
2 shared publications Hanmin Lee
Fetal Treatment Center, Department of Surgery, University of California, San Francisco
2 shared publicationsHong-Wei Wu
2 shared publicationsLarry Wang
Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA
2 shared publications
Latest Publications
- 15 September 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 254
The role of spatial transcriptomics in exploring the tumor microenvironment in neuroblastoma
- 15 September 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 254
The role of spatial transcriptomics in exploring the tumor microenvironment in neuroblastoma
- Open Access
- 26 August 2026
- Published by Elsevier in Cancer Letters
- Vol. 660
A human stem cell model of neuroblastoma identifies four chromosome 17q genes that drive tumor initiation and progression
- 26 August 2026
- Published by Elsevier in Cancer Letters
- Vol. 660
Open AccessA human stem cell model of neuroblastoma identifies four chromosome 17q genes that drive tumor initiation and progression
- Open Access
- 18 December 2020
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (2) , e001560
Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice
Background Immunotherapy with anti-disialoganglioside dinutuximab has improved survival for children with high-risk neuroblastoma (NB) when given after induction chemotherapy and surgery. However, disease recurrence and resistance persist. Dinutuximab efficacy has not been evaluated when initiated before primary tumor removal. Using a surgical mouse model of human NB, we examined if initiating dinutuximab plus ex vivo-activated natural killer (aNK) cells before resection of the primary tumor improves survival. Methods In vitro, human NB cells (SMS-KCNR-Fluc, CHLA-255-Fluc) were treated with dinutuximab and/or aNK cells and cytotoxicity was measured. In vivo, NB cells (SMS-KCNR-Fluc, CHLA-255-Fluc, or COG-N-415x PDX) were injected into the kidney of NOD-scid gamma mice. Mice received eight intravenous infusions of aNK cells plus dinutuximab beginning either 12 days before or 2 days after resection of primary tumors. Tumors in control mice were treated by resection alone or with immunotherapy alone. Disease was quantified by bioluminescent imaging and survival was monitored. aNK cell infiltration into primary tumors was quantified by flow cytometry and immunohistochemistry at varying timepoints. Results In vitro, aNK cells and dinutuximab were more cytotoxic than either treatment alone. In vivo, treatment with aNK cells plus dinutuximab prior to resection of the primary tumor was most effective in limiting metastatic disease and prolonging survival. aNK cell infiltration into xenograft tumors was observed after 1 day and peaked at 5 days following injection. Conclusion Dinutuximab plus aNK cell immunotherapy initiated before resection of primary tumors decreases disease burden and prolongs survival in an experimental mouse model of NB. These findings support the clinical investigation of this treatment strategy during induction therapy in patients with high-risk NB.
- 18 December 2020
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (2) , e001560
Open AccessInitiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice
Background Immunotherapy with anti-disialoganglioside dinutuximab has improved survival for children with high-risk neuroblastoma (NB) when given after induction chemotherapy and surgery. However, disease recurrence and resistance persist. Dinutuximab efficacy has not been evaluated when initiated before primary tumor removal. Using a surgical mouse model of human NB, we examined if initiating dinutuximab plus ex vivo-activated natural killer (aNK) cells before resection of the primary tumor improves survival. Methods In vitro, human NB cells (SMS-KCNR-Fluc, CHLA-255-Fluc) were treated with dinutuximab and/or aNK cells and cytotoxicity was measured. In vivo, NB cells (SMS-KCNR-Fluc, CHLA-255-Fluc, or COG-N-415x PDX) were injected into the kidney of NOD-scid gamma mice. Mice received eight intravenous infusions of aNK cells plus dinutuximab beginning either 12 days before or 2 days after resection of primary tumors. Tumors in control mice were treated by resection alone or with immunotherapy alone. Disease was quantified by bioluminescent imaging and survival was monitored. aNK cell infiltration into primary tumors was quantified by flow cytometry and immunohistochemistry at varying timepoints. Results In vitro, aNK cells and dinutuximab were more cytotoxic than either treatment alone. In vivo, treatment with aNK cells plus dinutuximab prior to resection of the primary tumor was most effective in limiting metastatic disease and prolonging survival. aNK cell infiltration into xenograft tumors was observed after 1 day and peaked at 5 days following injection. Conclusion Dinutuximab plus aNK cell immunotherapy initiated before resection of primary tumors decreases disease burden and prolongs survival in an experimental mouse model of NB. These findings support the clinical investigation of this treatment strategy during induction therapy in patients with high-risk NB.
- 1 September 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 253, 115-120
The Effect of Gross Total Resection on Patients with Pleuropulmonary Blastoma
- 1 September 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 253, 115-120
The Effect of Gross Total Resection on Patients with Pleuropulmonary Blastoma
- 1 August 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 252, 63-68
Postoperative Hypoparathyroidism After Total Thyroidectomy in Children
- 1 August 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 252, 63-68
Postoperative Hypoparathyroidism After Total Thyroidectomy in Children
- 1 May 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 249, 8-12
The Clinical Management and Outcomes of Pelvic Neuroblastic Tumors
- 1 May 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 249, 8-12
The Clinical Management and Outcomes of Pelvic Neuroblastic Tumors
- 1 March 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 247, 380-386
Predictors and Outcomes of Paramedian Incisional Hernia After Anterior Spine Exposure
- 1 March 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 247, 380-386
Predictors and Outcomes of Paramedian Incisional Hernia After Anterior Spine Exposure
- 23 November 2019
- Published by Springer Nature in Pediatric Surgery International
- Vol. 36 (3) , 317-324
The incidence of neuropathic pain after intercostal cryoablation during the Nuss procedure
Purpose Intercostal nerve cryoblation during the Nuss procedure for pectus excavatum decreases pain, opiate requirement, and hospital length of stay (LOS) compared to thoracic epidural analgesia. However, long-term complications of cryoablation, including neuropathic pain development, are not well studied. Methods We conducted a multi-institutional retrospective review of patients following intercostal nerve cryoablation during Nuss bar insertion (11/2015–7/2018). Patients completed the Leeds Assessment of Neuropathic Symptoms and Signs, a validated questionnaire for detecting neuropathic symptoms. Primary outcome was neuropathic pain development. Secondary outcomes included duration of chest numbness and LOS. T test was performed; p < 0.05 is significant. Results 43 patients underwent intercostal cryoablation during the Nuss procedure. Ages at repair ranged 11–47 years (median 16). Patients were grouped by age: ≤ 21 years (30 patients) or older (13 patients). Mean LOS was shorter for the younger group, 2.0 versus 3.9 days (p = 0.03). No patients in the younger group, and three in the older, experienced neuropathic pain. Mean time to numbness resolution was shorter for the younger group, 3.4 versus 10.8 months (p = 0.003). Conclusion In pediatric patients, intercostal cryoablation provides effective analgesia following the Nuss procedure with minimal risk of post-operative neuropathic pain. Adult patients are at greater risk of experiencing neuropathic pain and prolonged numbness.
- 23 November 2019
- Published by Springer Nature in Pediatric Surgery International
- Vol. 36 (3) , 317-324
The incidence of neuropathic pain after intercostal cryoablation during the Nuss procedure
Purpose Intercostal nerve cryoblation during the Nuss procedure for pectus excavatum decreases pain, opiate requirement, and hospital length of stay (LOS) compared to thoracic epidural analgesia. However, long-term complications of cryoablation, including neuropathic pain development, are not well studied. Methods We conducted a multi-institutional retrospective review of patients following intercostal nerve cryoablation during Nuss bar insertion (11/2015–7/2018). Patients completed the Leeds Assessment of Neuropathic Symptoms and Signs, a validated questionnaire for detecting neuropathic symptoms. Primary outcome was neuropathic pain development. Secondary outcomes included duration of chest numbness and LOS. T test was performed; p < 0.05 is significant. Results 43 patients underwent intercostal cryoablation during the Nuss procedure. Ages at repair ranged 11–47 years (median 16). Patients were grouped by age: ≤ 21 years (30 patients) or older (13 patients). Mean LOS was shorter for the younger group, 2.0 versus 3.9 days (p = 0.03). No patients in the younger group, and three in the older, experienced neuropathic pain. Mean time to numbness resolution was shorter for the younger group, 3.4 versus 10.8 months (p = 0.003). Conclusion In pediatric patients, intercostal cryoablation provides effective analgesia following the Nuss procedure with minimal risk of post-operative neuropathic pain. Adult patients are at greater risk of experiencing neuropathic pain and prolonged numbness.
- Top Cited Papers
- 1 November 2019
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 54 (11) , 2250-2256
Intraoperative intercostal nerve cryoablation During the Nuss procedure reduces length of stay and opioid requirement: A randomized clinical trial
- 1 November 2019
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 54 (11) , 2250-2256
Top Cited PapersIntraoperative intercostal nerve cryoablation During the Nuss procedure reduces length of stay and opioid requirement: A randomized clinical trial